Biofrontera

Biofrontera Retained Earnings

The Retained Earnings of Biofrontera (B8FK.DE) as of Nov 21, 2026 is -128.70 M EUR. In the previous year, Retained Earnings was -124.74 M EUR — a change of 3.18% (lower).

Retained Earnings

-128.70 MEUR

YoY

3.18%

Last updated:

Retained Earnings of Biofrontera is 2025 -128.70 M EUR. Retained Earnings of Biofrontera was 2024 -124.74 M EUR. It decreases by 3.18% lower compared to the previous year.

The Biofrontera Retained Earnings history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Retained Earnings
Date
Retained Earnings
Jan 1, 2018
-145.38 M EUR
Jan 1, 2019
-152.71 M EUR
Jan 1, 2020
-165.73 M EUR
Jan 1, 2021
-136.62 M EUR
Jan 1, 2022
-180.79 M EUR
Jan 1, 2023
-181.16 M EUR
Jan 1, 2024
-124.74 M EUR
Jan 1, 2025
-128.70 M EUR
The Biofrontera Retained Earnings history
YEARRetained EarningsYoY
-128.70 MEUR+3.18%
-124.74 MEUR-31.14%
-181.16 MEUR+0.20%
-180.79 MEUR+32.33%
-136.62 MEUR-17.56%
-165.73 MEUR+8.53%
-152.71 MEUR+5.04%
-145.38 MEUR+6.50%
-136.51 MEUR+13.37%
-120.40 MEUR+9.63%
-109.82 MEUR+11.36%
-98.62 MEUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biofrontera Stock analysis

What does Biofrontera do? Biofrontera AG generates revenue by developing, selling, and distributing dermatological drugs and medical cosmetics for skin care, protection, and treatment. The company markets its portfolio which includes Ameluz for the photodynamic therapy of actinic keratoses, the PDT lamp BF-RhodoLED used in conjunction with Ameluz treatment, and Belixos, a herbal dermatological cream for conditions such as insect bites, burns, neurodermatitis, and psoriasis. These products address the needs of patients and healthcare providers seeking treatments for skin diseases and regenerative care of damaged skin. The firm also engages in the clinical development of drug candidates to expand its future revenue streams. This includes BF-derm1, a tablet containing an inhibitor that blocks histamine synthesis to prevent allergic reactions, and BF1, a selective serotonin receptor agent aimed at preventing migraines. Through its five wholly owned subsidiaries, notably B, Biofrontera AG supports these development and distribution activities from its headquarters in Leverkusen, Nordrhein-Westfalen. Biofrontera is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biofrontera stock

Retained Earnings of Biofrontera is -128.70 M EUR in 2025.

Retained Earnings of Biofrontera changed from -124.74 M EUR to -128.70 M EUR, representing a 3.18% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Retained Earnings Biofrontera since 2006 – with annual values, charts, and detailed analysis.

Retained earnings are the cumulative net income kept in the business rather than paid out as dividends. They fund future growth and operations.

Retained Earnings's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Retained Earnings's Biofrontera historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Biofrontera

All Key Metrics — Biofrontera